Introduction {#S0001}
============

Prostate cancer (PC) is the most frequent neoplasia diagnosed among men worldwide.[@CIT0001]

Castration-resistant prostate cancer (CRPC) is estimated to account from 10% to 27% of prostate cancer cases, depending on the regional and national area of reference, with over 70% of these cases diagnosed as metastatic CRPC (mCRPC).[@CIT0002],[@CIT0003] When localized, PC may have a good prognosis, whereas mCRPC may become lethal after a period of about 3--5 years, with an overall survival (OS) rate of about 29%.[@CIT0004],[@CIT0005]

The "standard of care" for mCRPC is chemotherapy based on docetaxel.[@CIT0006],[@CIT0007] Despite docetaxel significant survival improvement, with respect to the "pre-docetaxel era", mCRPC patients continue to have a poor prognosis.[@CIT0008]

In this view, since 2010 a fundamental shift has been occurring in the mCRPC treatment landscape, in particular, for chemotherapy-naïve mCRPC patients, through the Food and Drug Administration/European Medicine Agency approvals and the consequent introduction of several novel androgen receptor signaling axis-targeting agents into the marketplace. Thus, abiraterone acetate plus prednisone (AA+P) and enzalutamide (ENZA) have been a breakthrough in the clinical management of advanced PC treatment, showing prolonged survival, when administered before docetaxel chemotherapy. Moreover, their oral formulations favor the compliance to the therapy.[@CIT0003],[@CIT0009]--[@CIT0012]

In phase III studies, both AA+P and ENZA have improved the radiographic progression-free survival (rPFS) and the OS rates of mCRPC patients, compared with placebo, when administered before docetaxel.[@CIT0013],[@CIT0014] The two therapeutic strategies differ in terms of the presence of prednisone, that is an essential component of AA+P, and whose long-term exposure could generate complications for patients.[@CIT0015]--[@CIT0017] In particular, the most prevalent adverse events related to corticosteroids administration are hypertension, fracture or osteoporosis, nausea/vomiting/other gastrointestinal condition, cardiac condition, diabetes or hyperglycemia, and cataract.[@CIT0018]

Published head-to-head clinical trials with a direct comparison between ENZA and AA+P for the treatment of chemotherapy-naïve patients with mCRPC are lacking. Only few studies tried to evaluate the relative efficacy, cost-effectiveness, and resources absorption, indirectly comparing the two oral agents.[@CIT0019],[@CIT0020]

Since new therapeutic options can address the mCRPC patients, it is necessary to investigate not only cost and efficacy, but also the dimensions with emerging importance, such as safety, organizational, social and equity aspects, providing related evidence as required by the European EUnetHTA Core Model.[@CIT0021],[@CIT0022]

The present study aims at evaluating the implications related to the introduction of ENZA, and AA+P therapies, into the Italian National Healthcare Service, in terms of clinical outcomes, economic efficiency, and safety profile. The study also evaluated both the potential organizational advantages for the clinical centers taking in charge the oncologic patients, and the accessibility to care, in order to guarantee a positive impact for patients, for related caregivers, and, more in general, for citizens and entire communities, having this specific healthcare need. This is important for the creation of evidence-based information useful for the rationalization of the expenditure devoted to mCRPC treatments, thus also optimizing the patient clinical pathway.

Methods {#S0002}
=======

A Health Technology Assessment (HTA) analysis was implemented in 12 months (from 2017 to 2018) in Italy, comparing AA+P and ENZA therapies, as innovative therapeutic strategies, currently available for the mCRPC treatment.

Besides the assessment of the HTA dimensions, an appraisal phase was developed, thanks to the support of a Multiple Criteria Decision Analysis (MCDA) approach.[@CIT0022]--[@CIT0024]

Assessment of EUnetHTA dimensions {#S0002-S2001}
---------------------------------

Due to the multi-dimensional and multi-disciplinary nature of HTA, several aspects of the medical technologies (drugs) were analyzed as stated in the EUnetHTA Core Model: i) general relevance; ii) safety; iii) efficacy; iv) economic and financial impact; v) equity; vi) legal aspects; vii) social and ethical impact; and viii) organizational implications.[@CIT0022]

The above dimensions were deployed, taking into account scientific evidence, economic evaluations, and qualitative approaches.

### Literature review {#S0002-S2001-S3001}

Before starting the assessment of the dimensions, the PICO approach (Problem/population, Intervention, Comparator and Outcome) for the literature validation, was identified, thus defining the research question.[@CIT0025],[@CIT0026] In particular, the following PICO was discussed: i) P (population): mCRPC naïve population; ii) I (intervention): enzalutamide; iii) C (comparator): abiraterone acetate plus prednisone; iv) O (outcome): clinical effectiveness, in terms of overall survival and rPFS.

Literature evidence came from the systematic search of literature databases (Pubmed, Embase and Cochrane Library), from 2011, up to December 2017. The search terms were the followings: "Enzalutamide", "Abiraterone acetate", "hormone therapy", "Metastatic Castration--Resistant Prostate Cancer", "clinical effectiveness", "overall survival", "radiographic progression-free survival". It should be noted here, that in accordance with the use of GRADE, within an HTA exercise, only RCTs have been taken into consideration, focusing only on mCRPC naïve population, thus leading to high-quality evidence. Furthermore, besides the RCT study design, and its focus on a specific population, the defined inclusion criteria were the following: i) number of patients enrolled in the study (\>1,000) and ii) journal impact-factor (≥16). Peer-reviewed papers that explicitly described the clinical effectiveness of ENZA and AA+P within the naïve population affected by mCRPC, were consequently included, and synthetized according to a PRISMA flow diagram, thus mapping out the number of records (in terms of papers) identified, included and/or excluded, and the reasons for exclusion.[@CIT0027]

The validation of the scientific evidence available on the topic was performed through the New Castle--Ottawa Evaluation scale.[@CIT0028] A "star system" ranking scale has been developed, in which a study or evidence is judged, considering three broad perspectives: i) the selection of the study groups; ii) the comparability of the groups; and iii) the ascertainment of either the exposure or outcome of interest, for case-control or cohort studies, respectively.

Besides the qualitative assessment of evidence deployed by means of the above mentioned New Castle--Ottawa Evaluation scale, the papers included in the HTA have been also evaluated, following a quantitative approach, proposed by the IMPAQHTA model.[@CIT0029] In particular, literature evidence was briefly evaluated, with regard to the quality, completeness, and replicability, of the results, all of which were measured based on a 4-level evaluation scale.

Literature was used for highlighting efficacy profile in terms of OS, rPFS and safety profile (measured as drug-related adverse events rate). Since only primary evidence have been considered, the literature review proposed in the present paper collected high-quality efficacy and safety information.

In order to verify the efficacy and the safety profiles replicability and scalability, from the international to the Italian "real-life" setting, information derived through literature were also validated with the involvement of 10 experts (referring to 5 Italian hospitals) taking in charge mCRPC patients, thus presenting an Italian country-oriented approach. In this view, the personal perceptions of the professionals using the drugs were collected, following specific items of relevance, according to the EUnetHTA Core Model.[@CIT0022]

### Economic evaluations {#S0002-S2001-S3002}

For economic dimension evaluation, pharmaco-economics tools, and budget impact analysis were used ([Table 1](#T0001){ref-type="table"}). Information was gathered according to the standard clinical pathway performed in the 5 Italian hospitals involved in the study.Table 1Methods used for the assessment of each HTA dimensionDimensionSub-dimensionQuantitative and qualitative metrics for the evaluation**General relevance**Target population eligible to AA+P or ENZA treatmentmCRPC prevalence and incidence rate of the Italian male population, derived from scientific evidence[@CIT0003],[@CIT0037],[@CIT0040],[@CIT0041]**Safety**Rate of mild, moderate and severe adverse events% incidence of adverse events, derived from literature evidence, whose clinical management and treatment were economically valorized.[@CIT0013],[@CIT0014]Qualitative perception on the real-world safety profileThe 10 mCRPC experts involved in the analysis, completed a comparative qualitative questionnaire, based on a 7-item Likert scale (ranging from −3 to +3), considering the following items, thus retrieving a country-oriented safety indicator: i) development of severe drug-related adverse events; ii) development of mild and moderate drug-related adverse events; iii) development of drug interactions; iv) overall degree of safety and tolerability of hormone therapy; v) impact of the hormone therapy on pain perceived by the patient; vi) impact of side effects related to the use of prednisone; vii) impact of the hormone therapy on the increase systemic exposure, in association with food.**Efficacy**Efficacy indicatorsOverall survival (OS) and radiographic progression-free survival (rPFS) rates, derived from randomized clinical trials on the topic, comparing AA+P or ENZA with placebo.[@CIT0013],[@CIT0014]Qualitative perception on the real-world effectiveness profileThe 10 mCRPC experts involved in the analysis, completed a comparative qualitative questionnaire, based on a 7-item Likert scale (ranging from −3 to +3), considering the following items, thus retrieving a country-oriented effectiveness indicator: i) improvement in patient reported outcomes; ii) improvement in the overall survival; iii) improvement in the progression-free survival; iv) decrease in the tumor mass; v) time to start treatment with cytotoxic chemotherapy; vi) prostate specific antigen response, in terms of a reduction equal to ≥50% with respect to the baseline; vii) time to prostate specific antigen progression.**Economic and financial impact**Activity Based Costing AnalysisEconomic evaluation of the clinical pathway of mCRCP patients assuming AA+P or ENZA.Cost-effectiveness analysisCost-effectiveness value, calculated as clinical pathway costs divided by efficacy data (OS), derived from literature evidence.[@CIT0013],[@CIT0014]Budget impact analysisThe above-mentioned clinical pathway cost per patient was multiplied by the total number of patients diagnosed with mCRPC, thus comparing a baseline with an innovative scenario.**Equity impact**Equity perceived aspectsThe 10 mCRPC experts involved in the analysis, completed a comparative qualitative questionnaire, based on a 7-item Likert scale (ranging from −3 to +3), considering the following items: i) access to care at a local level; ii) access to care for person of a legally protected status; iii) impact on the hospital waiting lists; iv) generation of health migrations; v) presence of factors influencing the patient's ability and autonomy; vi) protection of persons of a legally protected status; vii) level of iniquity.**Social and ethical impact**Social and ethical perceived aspectsThe 10 mCRPC experts involved in the analysis completed a comparative qualitative questionnaire, based on a 7-item Likert scale (ranging from −3 to +3), in accordance with the following aspects:\
i) ability of the drug to protect the patients' autonomy; ii) ability of the drug to protect the human rights; iii) ability of the drug to protect the patients' integrity; iv) ability of the drug to protect the patients' dignity; v) the use of the drug guarantees the social values and the willingness to pay of the patient; vi) impact of the drug on social costs; vii) patients and citizens can have a good level of understanding of the drug; viii) impact of the drug on patients' satisfaction; ix) impact of the drug on the patient's perceived quality of life; x) impact of the drug on the care giver's life and perception; xi) impact of the drug on the patient's functional state; xii) ease of swallowing the tablet; xiii) impact on the daily intake of the drug, in terms of number of pills.Quantitative social costsDefinition of the number of hospital accesses for monitoring activities.**Legal impact**Legal perceived aspectsThe 10 mCRPC experts involved in the analysis completed a comparative qualitative questionnaire, based on a 7-item Likert scale (ranging from −3 to +3). In accordance with the following aspects: i) authorization level (national/European/international); ii) need to insert the technology into the registry at National and/or European level; iii) fulfillment of the safety requirements; iv) infringement of intellectual property rights; v) need to regulate the technology acquisition; vi) legislation covers the regulation of technology for all categories of patients.**Organizational**\
**impact**Organizational\
perceived aspectsThe 10 mCRPC experts involved in the analysis completed a comparative qualitative questionnaire, using a 7-item Likert scale (ranging from −3 to +3), in accordance with the following aspects.\
i) additional staff; ii) training course for the clinicians of reference; iii) training course for the healthcare professionals involved in the pathway; iv) hospital meetings required; v) impact of the drug on patient's management, in terms of follow-up monitoring activities; vi) impact of the drug on hospital waiting lists; vii) impact of the drug on treatment duration; viii) impact of the technology on the hospital purchasing processes; ix) impact of the drug on the internal processes; x) impact of the drug on the patient's clinical pathway.Organizational quantitative aspects Definition of the time spent for AA+P and ENZA monitoring activities.

The clinical pathway of mCRPC patients was described and standardized. The clinicians and pharmacists of reference approved the clinical pathway, with a Delphi method approach.[@CIT0030] The pathway analysis leads to the identification of the following five phases: 1) urology clinic; 2) radiological staging; 3) medical oncology; 4) hormonal pharmacological treatment; and 5) follow-up, in a time horizon of 12 months, and related activities, procedures, and professionals involved. In this view, the economic impact of a patient following this pathway, and receiving mCRPC treatments was determined, using these components. Drugs costs: the dosing schedules of ENZA and AA+P, were based on the Italian product labels;[@CIT0031],[@CIT0032] the cost of each drug was based on the Italian *ex-factory* price, considering the mandatory discounts required by law and the V.A.T. The recommended daily dose was determined according to the Summary of Product Characteristics, of each drug;[@CIT0033],[@CIT0034] the drugs costs were derived from the officially published NHS price list.Non-drug related costs: medical costs for mCRPC management, including the total amount of hematologic and cultural tests, diagnostic procedures, outpatient visits, medical examinations, hospital admissions.Cost of side effects management (laboratory tests, diagnostic procedures, clinician visits, hospital admissions): depending on the incidence and the applied therapeutic strategy, according to the literature.[@CIT0013],[@CIT0014]

The clinical pathway economic analysis was performed considering a time horizon of 12 months, and according to the 2017 Italian reimbursement tariffs of outpatients and hospital admissions.

The economic evaluation of an mCRPC patient pathway was completed with a cost-effectiveness and a budget impact analyses, taking into consideration efficacy and safety parameters, derived from phase III related studies.[@CIT0013],[@CIT0014] On one hand, the cost-effectiveness value indicator (CEV), in average terms, was determined to choose the technology that shows a better cost-effectiveness trade-off (calculated as cost per patient divided for the OS indicator, in terms of percentage of survived patients, considering a 12-month time horizon).[@CIT0035],[@CIT0036] Furthermore, the cost-effectiveness incremental value (ICER) was investigated, useful for the determination of the ratio between costs and the OS gained.[@CIT0035],[@CIT0036]

On the other hand, the budget impact analysis (BIA) compared a baseline scenario (in which all the eligible patients were treated with AA+P), with an innovative scenario (in which eligible patients were treated with either AA+P -- 66% or ENZA -- 34%). The above market shares used for defining the two scenarios were retrieved in accordance with real-life data, carried out in the 5 hospitals involved in the analysis, with a Delphi approach.[@CIT0030]

Two different projections were hypothesized, depending on the median treatment lengths, equal to 13.8 and 16.6 months, respectively.[@CIT0013],[@CIT0014] In particular, the healthcare expenditure evolution up to 3 years was estimated assuming the NHS perspective. The number of eligible patients was determined based on the Italian epidemiological prevalence and incidence rates, regarding the mCRPC pathology, of the male population.[@CIT0003],[@CIT0037]--[@CIT0039] In this view, 41,221 incident Italian males (being chemotherapy naïve) received a diagnosis of prostate cancer, with 33.5% could be classified as CRPC.[@CIT0040],[@CIT0041] Out of them, 80.50% could potentially progress to mCRPC, thus being considered eligible for therapy. It emerged that 11,116 naïve males would suffer from mCRPC in the Italian setting.

### Qualitative approach {#S0002-S2001-S3003}

Qualitative questionnaires derived from the EUnetHTA Core Model were administered to 10 mCRPC experts (6 medical oncologists and 4 experts from the Pharmaceutical Department), referring to 5 medium-size hospitals (at least, 1,140 ordinary and 59 day-hospital beds), treating oncological patients, who completed the questionnaire according to their own experience and perceptions.

The qualitative questionnaires were used for examining equity, social, legal, and organizational aspects, considering a comparative approach of the two technologies under assessment (ENZA and AA+P), in accordance with a 7-item Likert scale ranging from -- 3 to +3.

Detailed information with regard to the specific items related to each dimension is shown in [Table 1](#T0001){ref-type="table"}.

The appraisal phase {#S0002-S2002}
-------------------

After the assessment of the dimensions, the appraisal phase was conducted, in order to identify the drug presenting a higher final value, thus directly comparing AA+P and ENZA.

At first, as required by the operative implementation of MCDA approach at the institutional level, the 10 mCRPC experts who completed the qualitative HTA questionnaire prioritized the above dimensions by a rating scale ranging from 8 (more important dimension) to 1 (less important dimension).[@CIT0042] Then, an MCDA approach was applied.[@CIT0023],[@CIT0024] In particular, three evaluators (different from the ones performing the prioritization and the assessment) -- 2 Hospital Health Directors, and 1 health economist -- with an HTA, decision-making and organizational background, assigned to each sub-dimension (listed in [Table 1](#T0001){ref-type="table"}) a five-level mark (ranging from a minimum of 0 to a maximum of 4). Thanks to this approach, the experts suggested a final and synthetic mark to the quality and completeness of the information retrieved for both AA+P and ENZA, in the HTA report.

In conclusion, the identification of the final score for each drug was obtained by multiplying the standardized score, calculated for each dimension (average value derived from sub-dimensions), by the normalized value of priority. Thus, the higher the score acquired, the more preferable is the technology.

Statistical analysis {#S0002-S2003}
--------------------

Economic and qualitative data were first analyzed, considering descriptive statistics. Differences between AA+P and ENZA were evaluated, according to a significance level lower than 0.05 (*p*-value), thus using the Independent sample *T*-test.

Furthermore, with regard to the economic dimension, both a scenario and a sensitivity analyses were conducted, in order to verify the robustness of the results. At first, a scenario analysis was performed, on the basis of the uncertainty existing with regard to PC and CRPC incidence rate (the first ranging from 35,300 patients, to 44,525 patients; the second ranging from 33% to 34%), and the mCRPC prevalence rate (ranging from 85% to 75%).[@CIT0040],[@CIT0041] Starting from the above information, three different hypotheses of population were developed, thus defining an average population equal to 11,116 naïve mCRPC patients, ranging from a minimum scenario composed of 9,902 Italian males, and a maximum scenario composed of 11,354 Italian males, potentially eligible to oral treatment.

Second, a sensitivity analysis was performed, in order to verify the robustness of the results, in terms of cost and efficacy data, on the basis of the different OS percentages, within different time horizons, as revealed in the phase III studies, and the related clinical pathway cost.[@CIT0013],[@CIT0014] In addition, Bayesian statistics was performed, since Bayesian methods provide a complete paradigm for both statistical inference and decision-making under uncertainty. Beta and Gamma distributions were accordingly developed, in order to verify the robustness of the results, in presence of uncertainty factors (efficacy, clinical pathway cost, and CEV parameters were analyzed). The probability to have: i) any OS average value of the beta distribution of ENZA, higher with respect to AA+P; ii) any cost average value of the gamma distribution of ENZA, lower with respect to AA+P; and iii) any average CEV of the gamma distribution of ENZA lower with respect to AA+P, was evaluated.

Also for the appraisal phase results, an uncertainty analysis was conducted. With regard to the MCDA analysis, the prioritization phase consistency and the Beta distributions of the final results obtained for AA+P and ENZA were performed, in order to test their reliability.

Results {#S0003}
=======

Results from the assessment of EUnetHTA dimensions {#S0003-S2001}
--------------------------------------------------

### Results from literature review {#S0003-S2001-S3001}

The search for Mesh terms resulted in 261 records. Out of them, only 32 were assessed for eligibility. In accordance with the above-mentioned search strategy, only 3 articles met the inclusion criteria defined in the methodology section and focused on mCRPC naïve population, assuming either ENZA or AA+P.[@CIT0013],[@CIT0014],[@CIT0043] The other 29 articles had different aims, without focusing the attention on efficacy/safety data, nor reporting ongoing studies, nor presenting observational studies (without being high-quality RCTs, as presented in [Figure 1](#F0001){ref-type="fig"}).Figure 1Prisma flow chart.

The literature review revealed the lack of scientific evidence, concerning the head-to-head comparison between AA+P and ENZA in terms of safety and clinical efficacy. Despite the above missing information, the articles included in the analysis, presented quality and reliable data assessed, being RCTs. In particular, in accordance with the New Castle--Ottawa Evaluation Scale, the risk of bias was not high ([Table 2](#T0002){ref-type="table"}). The control group was accordingly determined, the outcomes measurement proved to be relevant in most cases, and both positive and negative outcomes were determined and explained in the evidence. The quantitative assessment of literature confirmed the quality, the completeness and the replicability of the results ([Table 2](#T0002){ref-type="table"}).Table 2Qualitative and quantitative assessment of scientific evidence included in the HTA report**Qualitative assessment-- New Castle--Ottawa Scale**[@CIT0028]**SelectionComparabilityOutcome**Ryan et al, 20154/42/23/3Beer et al, 20174/42/23/3Loriot et al, 20154/42/23/3**Quantitative assessment - IMPAQHTA model[@CIT0029]QualityReplicabilityCompleteness**Ryan et al, 2015444Beer et al, 2017444Loriot et al, 2015343

The clinical efficacy was derived from the above randomized clinical trials that enrolled the naïve patients' population.[@CIT0013],[@CIT0014] Both drugs resulted in an improved OS versus placebo (AA+P: 34.7 months; ENZA: 35.3 months), whereas the increase of rPFS was 16.5 months for AA+P and 20 months for ENZA. In particular, focusing on the therapeutic success within a 12-month time horizon, it emerged an OS rate equal to 91% for ENZA and equal to 88% for AA+P. For the safety profile, [Table 3](#T0003){ref-type="table"} shows the rate of adverse events and the economic evaluation of the related clinical pathway management, in a 12-month time horizon.[@CIT0013]--[@CIT0019] AA+P was associated with a higher development of adverse events, with consequent economic resources absorption for the patient's management and care, which is +234% higher than ENZA (*p*-value=0.000).Table 3Rate and economic evaluation of drug-related adverse events**Adverse eventsEconomic evaluationRate of adverse events**\
**AA+PRate of adverse events**\
**ENZAEconomic evaluation of AA+P adverse eventsEconomic evaluation of ENZA adverse eventsAcute renal failure**3,826.57€--1.00%--38.27€**Adrenocortical insufficiency**3,529.64€0.40%-14.12€--**Asthenia/Fatigue**315.29€1.90%2.30%5.99€7.25€**Alanine Transferase increased**364.56€5.30%0.20%19.32€0.73€**Aspartate Aminotransferase  increased**364.56€2.70%--9.84€--**Atrial fibrillation**2,407.28€1.60%0.20%38.52€4.81€**Back pain**527.90€--1.70%--8.97€**Cardiac events**4,700.00€6.60%1.70%310.20€79.90€**Dyspnea**1,484.00€2.10%0.40%31.16€5.94€**Edema**487.30€0.30%0.10%1.46€0.49€**Fall**4,441.90€--1.10%--48.86€**Hematuria**336.73€1.10%0.90%3.70€3.03€**Hyperglycemia**1,491.62€5.60%-83.53€--**Hypertension**963.00€3.40%5.00%32.74€48.15€**Hypokalemia**1,809.96€2.40%-43.42€--**Joint swelling**5,636.42€1.80%1.10%39.28€24.00€**Lower respiratory tract infection**447.97€--1.00%--4.48€**Lymphopenia**5,636.42€7.50%--422.73€--**Non- pathological fracture**2,571.63€--1.40%--36.00€**Posterior Reversible Encephalopathy Syndrome (PRES)**2,077.00€--0.10%--2.08€**Seizure**3,289.00€--0.10%--3.29€**Total cost related to the management of drug-related adverse events1,056.02€316.25€**

The validation of the above theoretical efficacy and safety profiles, derived from international literature evidence, confirmed their replicability also for the Italian clinical practice, as suggested by the perceptions of the clinicians and pharmacists involved in the study (please see [Table 4](#T0004){ref-type="table"}).Table 4Qualitative dimensions evaluationEffectiveness profileAA+PENZAImprovement in patient reported outcomes1.251.25Improvement in the overall survival1.751.75Improvement in the progression-free survival1.252.00Decrease in the tumor mass1.251.25Time to start treatment with cytotoxic chemotherapy1.251.75Prostate specific antigen response, in terms of a reduction equal to ≥50% with respect to the baseline0.751.00Time to prostate specific antigen progression1.251.00**Average value for the effectiveness profile1.251.43Safety profileAA+PENZA**Development of severe drug-related adverse events0.000.25Development of mild and moderate drug-related adverse events−0.50−0.25Development of drug interactions0.500.50Overall degree of safety and tolerability of hormone therapy0.751.25Impact of the hormone therapy on pain perceived by the patient1.500.75Impact of side effects related to the use of prednisone−0.500.00Impact of the hormone therapy on the increase systemic exposure, in association with food−0.250.00**Average value for the safety profile0.210.36Ethical and social aspectsAA+PENZA**Ability of the drug to protect the patients' autonomy1.751.75Ability of the drug to protect the human rights2.252.25Ability of the drug to protect the patients' integrity2.52.5Ability of the drug to protect the patients' dignity1.51.5The use of the drug guarantees the social values and the willingness to pay of the patient−0.5−0.5Impact of the drug on social costs1.51.5Patients and citizens can have a good level of understanding of the drug2.52.5Impact of the drug on patients' satisfaction22.5Impact of the drug on the patient's perceived quality of life21.75impact of the drug on the care giver's life1.751.75Impact of the drug on the patient's functional state11Ease of swallowing the tablet1−1Impact of technology on the daily intake of the drug (number of pills)00**Average value for ethical and social aspects1.481.35Legal aspectsAA+PENZA**Authorization level (national/European/international)00Need to insert the technology into the registry at national and/or European level00Fulfillment of the safety requirements2.752.75Infringement of intellectual property rights00Need to regulate the acquisition of technology−1.25−1.25The legislation covers the regulation of technology for all categories of patients2.52.5***Average value for legal aspects**0.67**0.67*Equity aspectsAA+PENZA**Access to care on local level0.750.75Access to care for person of a legally protected status1.51.5Access to care for person with comorbidities−12Impact on hospital waiting lists00Generation of health migrations0.250.5Existence of factors influencing the patient's ability and autonomy00Protection of persons of a legally protected status0.750.75Level of iniquity−0.250**Average value for equity aspects0.250.69Organizational aspectsAA+PENZA**Additional Staff00Training course for the clinicians of reference11Training course for the healthcare professionals10.75Hospital meetings required00Impact of the drug on patients management in terms of follow-up monitoring activities−0.752.25Impact of the drug on hospital waiting lists00Impact of the drug on treatment duration1.251.25Impact of the technology on the hospital purchasing processes11.5Impact of the drug on the internal processes0.250.25Impact of the drug on the patient's clinical pathway0.751.25**Average value for organizational perception0.450.83**[^1]

### Results from the economic evaluations {#S0003-S2001-S3002}

The annual cost to treat an mCRPC patient was estimated of 50,709.25 € for AA+P and of 49,673.37 € for ENZA (*p*-value=0.000), as showed in [Table 5](#T0005){ref-type="table"}, according to the five different phases of the patient clinical pathway, and in a time horizon of 12 months. In particular, differences emerged regarding the drug and the follow-up costs, since AA+P required a higher number of medical accesses compared with ENZA (+70% monitoring activities, *p*-value =0.000), in the same time horizon of treatment. Gamma distributions for costs confirmed that considering a time horizon of 13.8 months, 16.6 months and 18 months, ENZA clinical pathway presented a probability to absorb lower economic resources equal to 66.63%, 50.00%, and 61.34%, respectively ([Figure 2](#F0002){ref-type="fig"}).Table 5Economic evaluation of mCRPC patient clinical pathwayPhaseAA+PENZA*p*-ValueUrology clinic127.01 €127.01 €Not significant, \>0.05Radiological staging383.34 €383.34 €Not significant, \>0.05Medical oncology8,096.63 €8,096.63 €Not significant, \>0.05Hormonal pharmacological treatment of new generation41,749.50 €40,861.59 €0.00Follow-up352.77 €204.80 €0.00**Total50,709.25 €49,673.37 €0.00** Figure 2Gamma distributions of AA+P and ENZA in terms of clinical pathway cost

Due to lower cost and higher efficacy, ENZA could be considered the "dominant" technology, thus being preferable from a cost-effectiveness point of view ([Table 6](#T0006){ref-type="table"}).[@CIT0044] In particular, focusing only on efficacy data, and considering a time horizon of 13.8 months, 16.6 months, and 18 months, ENZA presented a probability equal to 99.9%, 98.7%, and 99.7%, respectively, to achieve a higher OS rate ([Figure 3](#F0003){ref-type="fig"}).Table 6Cost-effectiveness analysisAA+PENZAClinical pathway50,709.25 €49,673.37 €Overall survival rate (12-month time horizon)88%91%**Cost effectiveness value57,624.1554,586.12ICER (incremental cost-effectiveness value)−34,529.3** Figure 3Beta distributions of AA+P and ENZA in terms of overall survival.

Furthermore, the innovative hormonal treatment presented a 84.82%, 99.80%, and 98.7% possibility to have the better trade-off between cost and effectiveness, with respect to AA+P, assuming a time horizon of 13.8 months, 16.6 months, and 18 months, respectively ([Figure 4](#F0004){ref-type="fig"}).Figure 4Gamma distributions of AA+P and ENZA in terms of cost-effectiveness value

Results from the budget impact analysis revealed that the NHS would benefit from ENZA adoption into the clinical practice, with economic savings, ranging from 1.46% to 1.61%, depending on the therapeutic strategy duration ([Table 7](#T0007){ref-type="table"}), for the treatment of 11,126 naïve males with mCRPC (average population). The same trend emerged considering both the minimum and the maximum population eligible to oral treatment.Table 7Budget impact analysis resultsBudget impact analysis, considering a treatment duration of 16.6 months, considering 11,116 patientsBaseline scenarioInnovative scenarioDifference (€)Difference (%)**12-month time-horizon**479,747,585 €473,036,612 €−6,710,973 €−1.40%**24-month time-horizon**661,315,466 €647,471,008 €−13,844,458 €−2.09%**36-month time-horizon**660,420,244 €651,735,450 €−8.684.794 €−1.32%**Total1,801,483,295 €1,772,243,070 €−29,240,225 €−1.62%Budget impact analysis, considering a treatment duration of 13.8 months, considering 11,116 patientsBaseline scenarioInnovative scenarioDifference (€)Difference (%)12-month time-horizon**479,747,585 €473,036,612 €−6,710,973 €−1.40%**24-month time-horizon**549,374,363 €540,135.475 €−9,238,888−1.68%**36-month time-horizon**549,024,059 €541,804.170 €−7.219,889−1.32%**Total1,578,146,007 €1,554,976,257 €−23,169,750 €−1.47%Budget impact analysis, considering a treatment duration of 16.6 months, considering 9,902 patientsBaseline scenarioInnovative scenarioDifference (€)Difference (%)12-month time-horizon**427,353,418 €421,375,363 €−5,978,055 €−1.40%**24-month time-horizon**589,091,916 €576,759,439 €−12,332,478 €−2.09%**36-month time-horizon**588,294,464 €580,558,153 €−7,736,311 €−1.32%**Total1,604,739,798 €1,578,692,955 €−26,046,843 €−1.62%Budget impact analysis, considering a treatment duration of 13.8 months, considering 9,902 patientsBaseline scenarioInnovative scenarioDifference (€)Difference (%)12-month time-horizon**427,353,418 €421,375,363 €−5,978,055 €−1.40%**24-month time-horizon**489,376,119 €481,146,228 €−8,229,891 €−1.68%**36-month time-horizon**489,064,072 €482,632,681 €−6,431,391 €−1.32%**Total1,405,793,609 €1,385,154,272 €−20,639,337 €−1.47%Budget impact analysis, considering a treatment duration of 16.6 months, considering 11,354 patientsBaseline scenarioInnovative scenarioDifference (€)Difference (%)12-month time-horizon**490,019,259 €483,164,600 €−6,854,659 €−1.40%**24-month time-horizon**675,474,613 €661,333,738 €−14,140,876 €−2.09%**36-month time-horizon**674,560,224 €665,689,484 €−8,870,741 €−1.32%**Total1,840,054,096 €1,810,187,822 €−29,866,274 €−1.62%Budget impact analysis, considering a treatment duration of 13.8 months, considering 11,354 patientsBaseline scenarioInnovative scenarioDifference (€)Difference (%)12-month time-horizon**490,019,259 €483,164,600 €−6,854,659 €−1.40%**24-month time-horizon**561,136,786 €551,700,088 €−9,436,698 €−1.68%**36-month time-horizon**560,778,982 €553,404,511 €−7,374,471 €−1.32%**Total1,611,935,027 €1,588,269,199 €−23,665,828 €−1.47%**

This cost saving could not be relegated only to the economic sphere. [Table 8](#T0008){ref-type="table"} shows that ENZA could be the preferable drug with a 41.18% reduction of specialist visits and blood examinations versus comparator (*p*-value=0.000), thus leading to a significant time saving per mCRPC patient management of about 38.65% mins (*p*-value=0.000).Table 8Follow-up monitoring activitiesFollow-up monitoring activitiesAA+PENZANDuration\
(minutes)Total duration\
(minutes)NDuration\
(minutes)Total duration\
(minutes)Number of specialist visits within the first three months after starting therapy6159031545Number of specialist visits between month 4 and month 123154521530Number of diagnostic and blood exams within the first three months after starting therapy685510385255Number of diagnostic and blood exams between month 4 and month 12285170285170**Total number of activities1710Total minutes spent for monitoring activities815500**

### Results from the qualitative approach {#S0003-S2001-S3003}

Focusing on the qualitative aspects ([Table 4](#T0004){ref-type="table"}), ENZA and AA+P could be considered super-imposable in the measurement concerning the ethical and social impact (ENZA: 1.35 vs AA+P: 1.48, *p*-value \>0.05) and the legal dimension (ENZA: 0.67 vs AA+P: 0.67, *p*-value \>0.05). The emerged difference in the average value of the ethical and social impact perceptions is particularly due to the swallowing difficulty of ENZA pills, given its big dimensions. High-level perceptions related to ENZA adoption surged about the equity (ENZA: 0.69 vs AA+P: 0.25, *p*-value \<0.05) and the organizational impact (ENZA: 0.83 vs AA+P: 0.45, *p*-value \<0.05).

### Results from the appraisal phase {#S0003-S2001-S3004}

The appraisal phase required both a prioritization of the dimensions and the implementation of a multi-criteria decision approach.

According to the opinions of the 10 mCRPC experts involved, the prioritization revealed that the most important aspect was the efficacy profile followed by safety and economic impact. The less relevant dimension appeared the legal impact since both drugs have received approval for use in the clinical practice. No statistically significant "between-professional" differences emerged regarding the prioritization of the dimensions: clinicians and pharmacists perceived value of importance was thus consistent to each other.

The results from the MCDA ([Table 9](#T0009){ref-type="table"}), highlighted a superior score for ENZA than the comparator (0.79 vs 0.60, *p*-value=0.000), thus suggesting the preferable treatment for mCRPC patients.Table 9Multi-criteria decision analysisDimensionsStandardized dimensionsNormalized prioritization valueFinal valueAA+PENZAAA+PENZAGeneral relevance0.8750.8750.100.090.09Safety0.5310.7500.190.100.15Efficacy0.7190.9690.220.160.22Economic and financial impact--0.3960.5630.140.050.08Equity aspects0.5630.8130.120.070.10Ethical and social Impact0.5420.7500.100.060.08Organizational impact0.5940.9060.080.050.07Legal impact0.6250.6250.040.030.03**Total4.8456.2510.600.79**[^2]

[Figure 5](#F0005){ref-type="fig"} depicts that the final value related to ENZA, is always higher than the one related to AA+P, confirming the preference in adopting ENZA, during the decision-making process.Figure 5Gamma distributions of AA+P and ENZA in terms of MCDA final value

Discussion {#S0004}
==========

During recent years, hormonal therapies have significantly changed the landscape of the mCRPC management. Clinical decisions about the mCRPC therapies remain largely consensus-based than evidence-based, given the lack of prospective head-to-head trials assessing the efficacy of the treatments.

The present study partially tried to overcome this knowledge gap by applying a multi-dimensional evaluation and showing the strengths and weaknesses of the two hormonal therapies currently available.

Thus, the appraisal phase revealed to decision makers that ENZA could be a technological option to be administered for this specific setting, with important benefits in terms of economic and organizational savings, safety profile and accessibility improvement. In particular, ENZA is related to less economic resources absorption than AA+P, resulting in a better cost-effectiveness indicator, and a feasible and sustainable 12-month budget impact, with economic savings ranging from 1.46% to 1.61%. This is partly due to the cost offset of a moderate incidence of adverse events and the lack of additional monitoring required.[@CIT0045],[@CIT0046]

Moreover, despite literature provides information about the economic impact approaching the topic with different methods and input data,[@CIT0020],[@CIT0045]--[@CIT0048] the present study revealed significant benefits of ENZA treatment from the patients management. A positive impact has emerged regarding the follow-up visits (ENZA: 2.25 vs AA+P: −0.75, *p*-value=0.000), and the entire patient clinical pathway (ENZA: 1.25 vs AA+P: 0.75, *p*-value=0.000).

A positive impact was also generated at the organizational level, in terms of improvement and optimization of mCRPC care and treatment, with the consequent possibility of freeing up resources, reducing hospital waiting lists and enhancing the accessibility to health care services. This aspect is linked to the fact that the therapeutic strategy AA+P includes prednisone, whose long-term exposure could generate side effects,[@CIT0015]--[@CIT0018],[@CIT0049]--[@CIT0051] thus requiring a higher number of follow-up monitoring steps and reducing the number of patients that could benefit from a mCRPC oral treatment (for example, diabetic population). In this view, the administration of ENZA could improve the accessibility to care for patients, who, given other diagnosed comorbidities (such as diabetes) could not assume AA+P, because of the presence of prednisone.

Furthermore, ENZA administration, characterized by fewer follow-up monitoring activities, could positively impact on the organizational aspects and on patients' social costs, in terms of reduction in productivity loss. Focusing on patients' perspective, clinicians declared that the investigated drugs improve patients' quality of life, due to their capability to prolong the OS.[@CIT0013],[@CIT0014] Previous studies strengthened this consideration: both ENZA and AA+P are associated with reduced risk for degradation in all the Functional Assessment of Cancer Therapy-Prostate subscales-FACT-P --compared to placebo.[@CIT0043],[@CIT0052]--[@CIT0054]

To the best of the authors' knowledge, this study could be considered the first attempt to fully evaluate the implications derived from ENZA and AA+P administration, into the Italian clinical practice, thus also paving the way to the possibility to perform an HTA exercise on drugs, whose efficacy and safety profiles have been already validated and approved with the development of proper randomized control trials. Moving on from these premises, it should be noted that Italy is an HTA user, without being an HTA doer: this is the rational behind the use of evidence-based information derived from RCTs, even if performed in other Countries, avoiding the duplication principle of scientific evidence. In this view, the value of drugs is strictly related to the strength, level, and reliability of the evidence-based information coming from literature review, in particular from primary evidence (such as RCTs or series of RCTs). With regard to the full assessment, with the exception of the efficacy and safety dimensions, all the information presented a country-oriented approach, with the involvement of 5 Italian hospitals taking in charge mCRPC patients. The health care services may consider the results provided by the present study as an opportunity to insert mCRPC patients in the most adequate oral treatment arm, guaranteeing a personalized clinical pathway, thus becoming more efficient and effective, and supporting the decision-making process with the deployment of innovative aspects, such as the organizational impact and the accessibility measure, particularly interesting in the drug landscape. In terms of limitations, despite the results of the present study could provide solutions to scholars and practitioners on the topic, it should be noted that evidence-based information about safety and efficacy, did not rely on prospective, randomized, controlled, head-to-head trials comparing ENZA and AA+P since it was based on accepted methodology for indirect comparison.[@CIT0055] In this view, further analysis may complement the present HTA analysis, in order to understand costs and advantages of clinical outcome, derived from the real-life clinical practice, and concerning the specific Italian setting.

Conclusion {#S0005}
==========

As the innovative ENZA and AA+P treatments have been introduced in the market and approved for a broader mCRPC population, public and health care services concern has grown, regarding the impact of the drugs-related costs, which are most expensive compared to the standard of mCRPC care.[@CIT0056]

The results of this study provide helpful evidence-based information to policy-makers through the examinations of the relative values of intervention, for deciding on the efficient and equitable allocation of health care resources, since it emerged that compliance, patients profile and cost could play an important role in the clinical practice decision-making process.
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